• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Our people > Leadership > Executive Team
Laurent Fraisse

Laurent Fraisse

Research & Development Director, DNDi

  • Laurent Fraisse
  • @fraisse47

Laurent Fraisse joined the Drugs for Neglected Diseases initative (DNDi) as Research & Development (R&D) Director and Executive Team member in October 2019. In this capacity he drives DNDi’s science strategy and oversees all research and clinical activities worldwide.

Laurent is an experienced biotechnology and pharmaceutical executive, and a leading expert in infectious diseases, having led R&D for large pharmaceutical firms such as Sanofi and Evotec, and served as chair of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Strategic Governing Group dedicated to infectious diseases. 

Laurent joined Sanofi in 1999 after a ten-year tenure as a science leader in Elf Atochem. During 20 years at Sanofi, he rose to serve as Vice President for Infectious Disease R&D, addressing medical needs in bacterial, parasitic, and viral related infections. He then joined Evotec as Executive Vice President for infectious diseases with the mission to accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives.

Laurent graduated from the Ecole Nationale Supérieure d’Agronomie in Rennes, France, with a specialty in Biochemistry and was awarded a PhD in Biotechnology by the Institut National Polytechnique in Toulouse in 1993.

Featured news & publications

Loading...
  • Mieux connaître et parfois mieux combattre les champignons microscopiques dangereux qui sont partout
  • Comment la Guinée s’est débarassée de la maladie du sommeil?
  • Interview de Laurent Fraisse sur les besoins pédiatriques liés aux maladies tropicales négligées
  • Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
  • Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains
  • Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
  • Facing the escalating burden of dengue: Challenges and perspectives
  • Il est difficile de garder les maladies tropicales négligées à l’agenda politique
  • Need for a standardized translational drug development platform: Lessons learned from the repurposing of drugs for COVID-19
  • Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Featured events

Loading...
  • MSF Scientific Days
  • ICAR 2023
  • Bridging diagnostic gaps to defeat NTDs
  • Improving access to NTD health products to achieve the 2030 Roadmap target
  • WuXi Healthcare Forum 2021

Our global footprint

Loading...
Doctors talking with patient in hospital

DNDi DRC

Female healthcare worker taking care of a little girl

DNDi Eastern Africa

DNDi Japan

Female patient discussing with doctor

DNDi Latin America

Female doctor with a patient in a hospital

DNDi North America

Community worker talking with people in a rural village

DNDi South Asia

Malaysian doctor talking with a man in a hospital

DNDi South-East Asia

Two people speaking in an office

DNDi Switzerland

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License